SuperworthLucid Diagnostics LUCD
- Market cap
- $83.5M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 15.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $5.4M
- +25% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
Lucid Diagnostics trades at 15.3× sales. Revenue was $5.4M over the last twelve months, up 25% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $783K+930% | $1M+829% | $1M+124% | $976K+514% | $1.2M+50% | $1.2M+15% | $828K−17% | $1.2M+19% | $1.2M+3% | $1.5M+26% | $1.3M+52% | $1.5M+27% | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | $1.6M | $1.6M | n/a | n/a | $1.6M+5% | $1.4M−8% |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | −$723K | −$400K | n/a | n/a | −$369K−49% | $29K |
| R&D | $1.6M−40% | $1.9M−22% | $1.5M−21% | $1.4M−25% | $1.7M+3% | $1.5M−24% | $1.4M−5% | $1.3M−9% | $1.3M−24% | $1.7M+19% | $1.2M−16% | $1.2M−5% |
| SG&A | $8.2M−15% | $8.6M−18% | $8.3M−25% | $9.1M+16% | $9.4M+15% | $9.9M+15% | $10.2M+24% | $9.6M+6% | $9.9M+5% | $11.8M+20% | $10.4M+2% | $11.5M+20% |
| −$11.1M−23% | −$11.5M−24% | −$10.8M−25% | −$11.2M−3% | −$11.7M+5% | −$12.4M+8% | −$12.5M+16% | −$11.4M+2% | −$11.8M+1% | −$14M+13% | −$12.1M−3% | −$12.8M+12% | |
| Interest expense | $149K | $11K | $12K−64% | $6K−97% | $1K−99% | $7K−36% | $9K−25% | $6K+0% | $2K+100% | $6K−14% | $6K−33% | $4K−33% |
| Pre-tax income | −$14.2M−1% | −$10.8M−28% | −$10.6M−35% | −$11M−3% | −$12.4M−13% | −$11.5M+7% | −$26.9M+154% | −$4.4M−60% | −$10.4M−16% | −$16.3M+41% | −$13.9M−48% | −$11.7M+163% |
| n/a | n/a | n/a | n/a | n/a | n/a | $0 | $0 | n/a | n/a | $0 | $0 | |
| Net income | −$14.2M−1% | −$10.8M−28% | −$10.6M−35% | −$11M−3% | −$12.4M−13% | −$11.5M+7% | −$26.9M+154% | −$4.4M−60% | −$10.4M−16% | −$16.3M+41% | −$13.9M−48% | −$11.7M+163% |
| −$0.34−13% | −$0.26−35% | −$0.40+0% | −$0.23−15% | −$0.25−27% | −$0.20−23% | −$0.52+30% | −$0.08−65% | −$0.10−60% | n/a | n/a | n/a | |
| 41.9M+15% | 42.3M+13% | 45M+10% | 48.2M+15% | 50.4M+20% | 58.4M+38% | 68.8M+53% | 99M+105% | 108.2M+115% | n/a | n/a | n/a |
Gross profit: 4 periods, Q1 FY25 to Q2 FY26: not printed by the filing, worked out from its own lines.
Interest expense: Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 5 periods, Q4 FY20 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY20 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Lucid Diagnostics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LUCDLucid Diagnostics | $83.5M | n/m | n/a | 15.3× | +25% | n/m | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| Peer median | $257M | 19.7× | 18.7× | 1.6× | +5% | 6.9% |
More on Lucid Diagnostics
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .